Target intelligence / Profile preview

26S proteasome 20S core subunit beta 1 and beta 2 (PSMB6 and PSMB7)

Target
PSMB6 and PSMB7
Molecular classification
Enzyme, Threonine protease, Proteasome complex
01

Overview

The 26S proteasome is a massive multi-subunit protease complex essential for maintaining cellular protein homeostasis by degrading misfolded or short-lived proteins tagged with ubiquitin (UniProt P28072, Q99436). The 20S core particle serves as the catalytic engine of this complex, containing three pairs of active sites: the beta 1 (PSMB6) subunit providing caspase-like activity, the beta 2 (PSMB7) subunit providing trypsin-like activity, and the beta 5 subunit providing chymotrypsin-like activity (PubMed: 26151217). These subunits utilize a unique N-terminal threonine residue to perform peptide bond hydrolysis. In hematological malignancies like multiple myeloma, cells are highly dependent on proteasome activity to manage the high volume of immunoglobulin production; thus, inhibiting these subunits leads to the accumulation of toxic protein aggregates, endoplasmic reticulum stress, and programmed cell death (StatPearls: NBK542311). While many clinical proteasome inhibitors primarily target the beta 5 subunit, secondary inhibition of the beta 1 and beta 2 subunits is often required to achieve maximal therapeutic efficacy and overcome drug resistance (PubMed: 21112705).

Other names
Proteasome subunit beta type-6Proteasome subunit beta type-720S proteasome subunit beta-120S proteasome subunit beta-2PSMB6PSMB7Macropain subunit deltaMacropain subunit Z
02

Mechanism of action

Inhibition of the catalytic N-terminal threonine residue within the beta subunits of the 20S core, preventing the degradation of polyubiquitinated proteins and inducing proteotoxic stress and apoptosis.

03

Biological functions

Protein degradationUbiquitin-proteasome system (UPS)Cell cycle regulationApoptosisAntigen processingSignal transduction
04

Disease associations

Multiple myelomaMantle cell lymphomaInflammationAutoimmune diseaseNeurodegenerative disease
05

Safety considerations

Peripheral neuropathyThrombocytopeniaNeutropeniaCardiotoxicityGastrointestinal toxicityIncreased risk of Herpes Zoster reactivation
06

Interacting drugs

Bortezomib

5 more in the full profile.

07

Biomarkers

Proteasome activity (ex vivo enzymatic assays)Accumulation of polyubiquitinated proteinsM-protein levels (in Multiple Myeloma)Serum free light chains

Beyond the preview

Go deeper on 26S proteasome 20S core subunit beta 1 and beta 2 (PSMB6 and PSMB7).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 26S proteasome 20S core subunit beta 1 and beta 2 (PSMB6 and PSMB7).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call